Dexcom shares jump as quarterly results ease Abbott-tied wearables concerns

Dexcom rose more than 5% to $84.47 after its third-quarter report showed 11% sales growth, a profit beat, and no pricing degradation, countering Abbott's earlier warning on diabetes wearables. The company raised the bottom and midpoint of full-year sales guidance to $5.2 billion to $5.25 billion and reiterated belief that a Medicare coverage expansion proposal for non-insulin patients will come by year-end.